Investigating the role of Epstein-Barr Virus in certain lymphomas
Official title: Targeting EBV-associated lymphomas
Funded at Univ of North Carolina Chapel Hill · NIH-11001649 · Data updated 2026-11-12
This study is looking at how the Epstein-Barr Virus (EBV) might help cause certain types of lymphomas and is focusing on a protein called FAM72A to find new ways to treat these cancers, with the hope that patients can help in discovering better treatment options.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | September 10, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $645,012 |
| NIH project number | 1U01CA294800-01 |
| Project ID | NIH-11001649 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with EBV-positive lymphomas, such as Burkitt's lymphoma or diffuse large B cell lymphoma.
✕Less likely to help
Patients with lymphomas not associated with Epstein-Barr Virus may not benefit from this research.
What this research studies
This research focuses on understanding how the Epstein-Barr Virus (EBV) contributes to the development of various types of lymphomas, particularly those associated with EBV. The team will explore the role of a specific protein, FAM72A, which is found to be highly expressed in EBV-positive lymphomas. By studying the mechanisms through which EBV influences lymphoma development, the research aims to identify potential therapeutic targets. Patients may be involved in this research to help uncover new treatment strategies for these malignancies.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with EBV-associated lymphomas.
How similar studies have gone: Previous research has shown promising results in targeting viral mechanisms in cancer, suggesting that this approach may lead to significant advancements.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Damania, Blossom a — Univ of North Carolina Chapel Hill
- Study coordinator: Damania, Blossom a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.